Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Neurology | Musculoskeletal

Multiple Sclerosis

Alabama

Birmingham : Research Center

Investigational Oral Medication for RRMS

Huntsville : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Arizona

Gilbert : Research Center

Investigational Oral Medication for RRMS

Phoenix : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Phoenix : Research Center

Investigational Oral Medication for RRMS

Phoenix : Research Center

Investigational Oral Medication for RRMS

Tucson : Northwest NeuroSpecialists, PLLC

Clinical Research Study Available for People Diagnosed with Multiple Sclerosis

Tucson : Northwest NeuroSpecialists, PLLC

Multiple Sclerosis Study

California

Auburn : Sutter Institute for Medical Research (SIMR)

Multiple Sclerosis Data Collection Study

Berkeley : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Berkeley : The REDI of Alta Bates Summit Medical Center

A research study for patients with symptoms of overactive bladder.

Downey : Los Amigos Research and Education, Environmental Health Services

A research study for patients with symptoms of overactive bladder.

La Jolla : Coordinated Clinical Research (La Jolla, CA)

Have you been diagnosed with Multiple Sclerosis? A clinical research study for Relapsing-Remitting MS is underway in your area.

Loma Linda : Research Center

Investigational Oral Medication for RRMS

Sacramento : Research Center

Investigational Oral Medication for RRMS

San Francisco : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

San Francisco : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Colorado

Boulder : Alpine Clinical Research Center

Add-on Therapy of an oral medication for patients with Multiple Sclerosis, currently using Avonex, Betaseron, or Rebif.

Boulder : Research Center

Investigational Oral Medication for RRMS

Boulder : Alpine Clinical Research Center New!

New medicine for patients with Multiple Sclerosis experiencing Neuropathic Pain

Boulder : Alpine Clinical Research Center New!

New Oral medication for reducing the rate of clinical relapses in patients with Relapsing Remitting Multiple Sclerosis (MS)

Centennial : 1st International Clinical Research Center

Do you have Relapsing Remitting Multiple Sclerosis?

Colorado Springs : Research Center

Investigational Oral Medication for RRMS

Fort Collins : Research Center

Investigational Oral Medication for RRMS

Connecticut

Fairfield : Associated Neurologists of Southern Connecticut

A research study for patients with symptoms of overactive bladder

New Haven : Research Center

Investigational Oral Medication for RRMS

Pawcatuck : CNS Research of CT, Inc.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Florida

Bradenton : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bradenton : Bradenton Research Center

A research study for patients with symptoms of overactive bladder

Bradenton : Bradenton Research

Bradenton Neurology, Inc. is participating in a nationwide research study for individuals who have been diagnosed with Multiple Sclerosis.

Maitland : Research Center

Investigational Oral Medication for RRMS

Melbourne : Melbourne Internal Medicine Associates (MIMA)

A research study for patients with symptoms of overactive bladder

Miami : University of Miami, Department of Neurology

A research study for patients with symptoms of overactive bladder.

Miami : Research Center

Investigational Oral Medication for RRMS

Naples : Research Center

Investigational Oral Medication for RRMS

Pompano Beach : Research Center

Investigational Oral Medication for RRMS

Saint Petersburg : Research Center

Investigational Oral Medication for RRMS

Sarasota : The Roskamp Institute, Clinical Trials Division

Do you or a loved one have relapsing remitting multiple sclerosis?

Sarasota : Research Center

Investigational Oral Medication for RRMS

Sarasota : Lovelace Scientific Resources - Sarasota

Multiple Sclerosis

Sarasota : The Roskamp Institute, Clinical Trials Division

Phase III study comparing different doses of study drug with placebo for Relapsing Remitting Multiple Sclerosis (RRMS)

Sarasota : The Roskamp Institute, Clinical Trials Division

Phase III study for patients with Relapsing remitting Multiple Sclerosis

Tallahassee : Research Center

Investigational Oral Medication for RRMS

Tampa : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Vero Beach : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vero Beach : Research Center

Investigational Oral Medication for RRMS

Georgia

Atlanta : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Atlanta : Neurotrials Research, Inc.

Have you experienced symptoms that suggest multiple sclerosis?

Atlanta : Research Center

Investigational Oral Medication for RRMS

Augusta : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Illinois

Chicago : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Evanston : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Indiana

Fort Wayne : Research Center

Investigational Oral Medication for RRMS

Indianapolis : Research Center

Investigational Oral Medication for RRMS

Indianapolis : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Iowa

Des Moines : Research Center

Investigational Oral Medication for RRMS

Kansas

Kansas City : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kansas City : Research Center

Investigational Oral Medication for RRMS

Lenexa : MidAmerica Neuroscience Institute

Relapsing forms of Multiple Sclerosis study to evaluate the safety and tolerability of two doses of an oral study drug over 24 weeks (study 7)

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Wichita : Research Center

Investigational Oral Medication for RRMS

Kentucky

Lexington : Associates in Neurology, P.S.C.

A Phase 2 study of LY2127399, an AntiBaff Human Antibody vs placebo for subjects with Relapsing Remitting Multiple Sclerosis

Lexington : Associates in Neurology, P.S.C.

A phase 3 study of Alemtuzumab infusion once a year vs. Rebif for patients with Relapsing Remitting multiple sclerosis who have been on prior ABC treatment and have relapsed.

Lexington : Associates in Neurology, P.S.C.

A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.

Lexington : Research Center

Investigational Oral Medication for RRMS

Louisville : Research Center

Investigational Oral Medication for RRMS

Louisiana

Shreveport : Research Center

Investigational Oral Medication for RRMS

Maryland

Baltimore : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Baltimore : Research Center

Investigational Oral Medication for RRMS

Massachusetts

Bellingham : CNS Research of MA, Inc.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Boston : MGH - Massachusetts General Hospital

Healthy Children between the Ages of 4-17 years - Investigation of Biomarkers in Pediatric Patients with Demyelinating Disorders of the CNS

Boston : Research Center

Investigational Oral Medication for RRMS

Boston : Research Center

Investigational Oral Medication for RRMS

Hopedale : Research Center

Investigational Oral Medication for RRMS

Springfield : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Worcester : Research Center

Investigational Oral Medication for RRMS

Michigan

Bingham Farms : QUEST Research Institute

Treatment for Multiple Sclerosis (MS) - Associated Spasticity

Farmington Hills : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Farmington Hills : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Minnesota

Minneapolis : Research Center

Investigational Oral Medication for RRMS

Mississippi

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Missouri

Saint Louis : Research Center

Investigational Oral Medication for RRMS

Montana

Billings : Billings Clinic Research Center

Are you between the age of 18 and 65 with a diagnosis of Multiple Sclerosis?

Nevada

Las Vegas : Research Center

Investigational Oral Medication for RRMS

New Hampshire

Dover : Research Center

Investigational Oral Medication for RRMS

Lebanon : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New Jersey

Lawrenceville : AdvanceMed Research

The Dignity studies are phase III international multicenter, double-blind, randomized, placebo-controlled trials of botulinum toxin (BOTOX) in patients with spinal cord injury (SCI) or multiple sclerosis (MS); BOTOX is not yet licensed for these indications.

New Mexico

Albuquerque : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New York

Albany : Upstate Clinical Research, LLC

A Double-Blind, Placebo Controlled Multi-Center Study To Evaluate The Efficacy And Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

Albany : Research Center

Investigational Oral Medication for RRMS

Amherst : Research Center

Investigational Oral Medication for RRMS

Buffalo : Research Center

Investigational Oral Medication for RRMS

Buffalo : Research Center

Investigational Oral Medication for RRMS

Cedarhurst : Research Center

Investigational Oral Medication for RRMS

Columbus : Research Center

Investigational Oral Medication for RRMS

Mineola : Winthrop University Hospital Clinical Trials Center

Relapsing remitting multiple sclerosis

Mineola : Winthrop University Hospital Clinical Trials Center

Volunteers needed for a multiple sclerosis research study

New York : Mount Sinai Medical Center

A 21 WEEK STUDY TO EVALUATE SAFETY AND EFFICACY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS.

New York : Mount Sinai Medical Center

A 24-month, double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of FTY720 1.25mg and 0.5mg administered once daily versus placebo in patients with relapsing remitting multiple sclerosis

New York : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New York : Mount Sinai Medical Center

A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon beta 1-a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx Phase III)

New York : Mount Sinai Medical Center

A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis PROTOCOL: U2786g

New York : Mount Sinai Medical Center

ITN020AI: A Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patient with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS) (STAYCIS)

New York : Biomedical Research Alliance of New York

Multiple Sclerosis treated with Betaseron® - Adults

New York : Mount Sinai Medical Center

OMEGA-Oral Megadose Corticosteroid Therapy of Acute Exacerbations in Multiple Sclerosis

New York : Biomedical Research Alliance of New York

Relapsing Remitting Multiple Sclerosis (RRMS)

New York : Mount Sinai Medical Center

The Establishment of a Patient Registry and Initiation of Related Projects of the New York State Multiple Sclerois Consortium

Patchogue : Research Center

Investigational Oral Medication for RRMS

Plainview : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Plainview : Research Center

Investigational Oral Medication for RRMS

Rochester : University of Rochester Medical Center

A research study for patients with symptoms of overactive bladder.

Schenectady : Schenectady Neurological Consultants, PC

The TYSABRI Global Observational Program in Safety (TYGRIS) is a safety observational cohort study designed to obtain long-term safety data in multiple sclerosis (MS) patients treated with TYSABRI in a clinical practice setting.

Staten Island : Research Center

Investigational Oral Medication for RRMS

Stony Brook : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Stony Brook : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

North Carolina

Chapel Hill : UNC Chapel Hill/ UNC Hospital

A research study for patients with symptoms of overactive bladder

Charlotte : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Charlotte : Research Center

Investigational Oral Medication for RRMS

Charlotte : Research Center

Investigational Oral Medication for RRMS

Raleigh : Research Center

Investigational Oral Medication for RRMS

Salisbury : Central Carolina Neurology & Sleep, PA

Looking for MS Patients for a Quality of Life Study

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Winston Salem : Wake Forest University BMC

A research study for patients with symptoms of overactive bladder

Winston-Salem : Research Center

Investigational Oral Medication for RRMS

Ohio

Bellevue : Research Center

Investigational Oral Medication for RRMS

Cleveland : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Cleveland : Research Center

Investigational Oral Medication for RRMS

Columbus : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Dayton : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Oklahoma

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Oregon

Medford : Research Center

Investigational Oral Medication for RRMS

Portland : Research Center

Investigational Oral Medication for RRMS

Tualatin : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Pennsylvania

Erie : Research Center

Investigational Oral Medication for RRMS

Hershey : Research Center

Investigational Oral Medication for RRMS

Philadelphia : Thomas Jefferson University

A research study for patients with symptoms of overactive bladder

Philadelphia : Research Center

Investigational Oral Medication for RRMS

Pittsburg : Research Center

Investigational Oral Medication for RRMS

Pittsburgh : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Rhode Island

East Providence : Research Center

Investigational Oral Medication for RRMS

Providence : CNS Research of RI, Inc.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

South Carolina

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Tennessee

Cordova : Research Center

Investigational Oral Medication for RRMS

Franklin : Research Center

Investigational Oral Medication for RRMS

Knoxville : Volunteer Research Group

A research study for patients with symptoms of overactive bladder

Knoxville : Research Center

Investigational Oral Medication for RRMS

Nashville : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nashville : Research Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Texas

Dallas : Research Center

Investigational Oral Medication for RRMS

Galveston : Research Center

Investigational Oral Medication for RRMS

Houston : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Houston : Research Center

Investigational Oral Medication for RRMS

Round Rock : Research Center

Investigational Oral Medication for RRMS

San Antonio : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Utah

Salt Lake City : Research Center

Investigational Oral Medication for RRMS

Vermont

Bennington : Research Center

Investigational Oral Medication for RRMS

Burlington : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Burlington : Research Center

Investigational Oral Medication for RRMS

Virginia

Charlottesville : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Charlottesville : University of Virginia

UVa Department of Neurology seeks Men and Women ages 18-55 with Relapsing-Remitting Multiple Sclerosis for research study.

Newport News : Research Center

Investigational Oral Medication for RRMS

Richmond : McGuire Veterans Medical Center

A research study for patients with symptoms of overactive bladder

Richmond : Research Center

Investigational Oral Medication for RRMS

Vienna : Research Center

Investigational Oral Medication for RRMS

Washington

Kirkland : MS Center At Evergreen

A research study for patients with symptoms of overactive bladder.

Seattle : Research Center

Investigational Oral Medication for RRMS

Seattle : Research Center

Investigational Oral Medication for RRMS

Tacoma : Research Center

Investigational Oral Medication for RRMS

Washington, DC

Washington : Research Center

Investigational Oral Medication for RRMS

Wisconsin

Madison : Research Center

Investigational Oral Medication for RRMS

Milwaukee : Research Center

Investigational Oral Medication for RRMS

Australia

Adelaide, SA : Royal Adelaide Hospital

A research study for patients with symptoms of overactive bladder.

Adelaide, SA : Research Center

Investigational Oral Medication for RRMS

Adelaide, SA : Research Center

Investigational Oral Medication for RRMS

Camperdown, NSW : Research Center

Investigational Oral Medication for RRMS

Chatswood, NSW : Research Center

Investigational Oral Medication for RRMS

Clayton, VIC : Research Center

Investigational Oral Medication for RRMS

Fitzroy, VIC : Research Center

Investigational Oral Medication for RRMS

Geelong, VIC : Research Center

Investigational Oral Medication for RRMS

Heidelberg, VIC : Research Center

Investigational Oral Medication for RRMS

Kogarah, NSW : Research Center

Investigational Oral Medication for RRMS

Liverpool, NSW : Research Center

Investigational Oral Medication for RRMS

Melbourne, VIC : Research Center

Investigational Oral Medication for RRMS

Newcastle, NSW : Research Center

Investigational Oral Medication for RRMS

Austria

Graz, STYRIA : Research Center

Investigational Oral Medication for RRMS

Innsbruck, TYROL : Research Center

Investigational Oral Medication for RRMS

Linz, UPPER AUSTRIA : Research Center

Investigational Oral Medication for RRMS

Wien, VIENNA : Research Center

Investigational Oral Medication for RRMS

Belarus

Gomel, HOMYELRSKAYA : Research Center

Investigational Oral Medication for RRMS

Gomel, HOMYELRSKAYA : Research Center

Investigational Oral Medication for RRMS

Minsk, MINSK : Research Center

Investigational Oral Medication for RRMS

Minsk, MINSK : Research Center

Investigational Oral Medication for RRMS

Vitebsk, VITSYEBSKAYA : Research Center

Investigational Oral Medication for RRMS

Vitebsk, VITSYEBSKAYA : Research Center

Investigational Oral Medication for RRMS

Belgium

Antwerpen, ANTWERPEN : Research Center

Investigational Oral Medication for RRMS

Brugge, WEST-VLAANDEREN : Research Center

Investigational Oral Medication for RRMS

Charleroi, HAINAUT : Research Center

Investigational Oral Medication for RRMS

Diepenbeek, LIMBURG : Research Center

Investigational Oral Medication for RRMS

Edegem : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Leuven, FLEMISH BRABANT : Research Center

Investigational Oral Medication for RRMS

Liège, LIEGE : Research Center

Investigational Oral Medication for RRMS

Lommel, LIMBURG : Research Center

Investigational Oral Medication for RRMS

Lommel, LIMBURG : Research Center

Investigational Oral Medication for RRMS

Sijsele-Damme : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sijsele-Damme, WEST-VLAANDEREN : Research Center

Investigational Oral Medication for RRMS

Sijsele-Damme,WEST-VLAANDEREN : Research Center

Investigational Oral Medication for RRMS

Woluwe, BRUSSELS : Research Center

Investigational Oral Medication for RRMS

Woluwe, BRUSSELS : Research Center

Investigational Oral Medication for RRMS

Bosnia and Herzegovina

Banja Luka, Republic Srpska : Research Center

Investigational Oral Medication for RRMS

Banja Luka, Republic Srpska : Research Center

Investigational Oral Medication for RRMS

Sarajevo, B&H Federation : Research Center

Investigational Oral Medication for RRMS

Tuzla, B&H Federation : Research Center

Investigational Oral Medication for RRMS

Brazil

Campinas, SAO PAULO : Research Center

Investigational Oral Medication for RRMS

Porto Alegre, RIO GRANDE DO SUL : Research Center

Investigational Oral Medication for RRMS

São Paulo, SAO PAULO : Research Center

Investigational Oral Medication for RRMS

Bulgaria

Plovdiv : Research Center

Investigational Oral Medication for RRMS

Rousse : Research Center

Investigational Oral Medication for RRMS

Rousse : Research Center

Investigational Oral Medication for RRMS

Sofia : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sofia : Research Center

Investigational Oral Medication for RRMS

Sofia : Research Center

Investigational Oral Medication for RRMS

Stara Zagora : Research Center

Investigational Oral Medication for RRMS

Varna : Research Center

Investigational Oral Medication for RRMS

Varna : Research Center

Investigational Oral Medication for RRMS

Canada

Burnaby, BC : Research Center

Investigational Oral Medication for RRMS

Edmonton, AB : Research Center

Investigational Oral Medication for RRMS

Gatineau, QC : Research Center

Investigational Oral Medication for RRMS

Halifax, NS : Research Center

Investigational Oral Medication for RRMS

Levis, PQ : Research Center

Investigational Oral Medication for RRMS

Montreal, QC : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Montreal, QC : Research Center

Investigational Oral Medication for RRMS

Montreal, QC : Research Center

Investigational Oral Medication for RRMS

Ottawa, ON : Research Center

Investigational Oral Medication for RRMS

Quebec, QC : Research Center

Investigational Oral Medication for RRMS

Regina, SK : Research Center

Investigational Oral Medication for RRMS

Sherbrooke, QC : Research Center

Investigational Oral Medication for RRMS

Toronto, ON : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vancouver, BC : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Victoria, BC : Can-Med Clinical Research Inc.

A research study for patients with symptoms of overactive bladder

Victoria, BC : Dr. Steinhoff Clinical Research

A research study for patients with symptoms of overactive bladder.

Costa Rica

San José, San José : Research Center

Investigational Oral Medication for RRMS

Croatia

Osijek, Osijek-Baranja : Research Center

Investigational Oral Medication for RRMS

Osijek, Osijek-Baranja : Research Center

Investigational Oral Medication for RRMS

Rijeka, Primorje-Gorski Kotar : Research Center

Investigational Oral Medication for RRMS

Rijeka, Primorje-Gorski Kotar : Research Center

Investigational Oral Medication for RRMS

Zagreb : Research Center

Investigational Oral Medication for RRMS

Zagreb : Research Center

Investigational Oral Medication for RRMS

Czech Republic

Brno : Research Center

Investigational Oral Medication for RRMS

Jihlava : Research Center

Investigational Oral Medication for RRMS

Opava : Research Center

Investigational Oral Medication for RRMS

Ostrava : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ostrava : Research Center

Investigational Oral Medication for RRMS

Ostrava, North Moravia : Research Center

Investigational Oral Medication for RRMS

Ostrava-Moravska Ostrava : Research Center

Investigational Oral Medication for RRMS

Pardubice : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Plzen : Research Center

Investigational Oral Medication for RRMS

Prague : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Praha : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Praha 2 : Research Center

Investigational Oral Medication for RRMS

Praha 2 : Research Center

Investigational Oral Medication for RRMS

Praha 5, PRAHA : Research Center

Investigational Oral Medication for RRMS

Teplice : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Teplice : Research Center

Investigational Oral Medication for RRMS

Denmark

Arhus : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Estonia

Kuressaare : Research Center

Investigational Oral Medication for RRMS

Parnu : Research Center

Investigational Oral Medication for RRMS

Tallinn : Research Center

Investigational Oral Medication for RRMS

Tartu : Research Center

Investigational Oral Medication for RRMS

Finland

Helsinki : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Turku : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

France

Bobigny : Research Center

Investigational Oral Medication for RRMS

Bordeaux : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bordeaux : Research Center

Investigational Oral Medication for RRMS

Caen : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Caen cedex : Research Center

Investigational Oral Medication for RRMS

Clermont Ferrand : Research Center

Investigational Oral Medication for RRMS

Clermont-Ferrand : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Dijon : Research Center

Investigational Oral Medication for RRMS

Dijon : Research Center

Investigational Oral Medication for RRMS

Lille cedex : Research Center

Investigational Oral Medication for RRMS

Lyon : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lyon cedex 03 : Research Center

Investigational Oral Medication for RRMS

Marseille Cedex 9 : Research Center

Investigational Oral Medication for RRMS

Montpellier : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Montpellier : Research Center

Investigational Oral Medication for RRMS

Montpellier cedex 5 : Research Center

Investigational Oral Medication for RRMS

Nancy cedex : Research Center

Investigational Oral Medication for RRMS

Nice : Research Center

Investigational Oral Medication for RRMS

Nimes : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nîmes : Research Center

Investigational Oral Medication for RRMS

Paris : Research Center

Investigational Oral Medication for RRMS

Rennes : Research Center

Investigational Oral Medication for RRMS

Strasbourg, ALSACE : Research Center

Investigational Oral Medication for RRMS

Germany

Bad Neustadt/Saale, BAYERN : Research Center

Investigational Oral Medication for RRMS

Bamberg, BAYERN : Research Center

Investigational Oral Medication for RRMS

Bayreuth, BAYERN : Research Center

Investigational Oral Medication for RRMS

Berg, Starnberger See : Research Center

Investigational Oral Medication for RRMS

Berlin : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Berlin BERLIN : Research Center

Investigational Oral Medication for RRMS

Berlin, BERLIN : Research Center

Investigational Oral Medication for RRMS

Bochum, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

Düsseldorf, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

Düsseldorf, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

Erbach : Research Center

Investigational Oral Medication for RRMS

Erlangen, BAYERN : Research Center

Investigational Oral Medication for RRMS

Essen, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

Gießen, HESSEN : Research Center

Investigational Oral Medication for RRMS

Halle (Saale), SACHSEN-ANHALT : Research Center

Investigational Oral Medication for RRMS

Halle (Saale), SACHSEN-ANHALT : Research Center

Investigational Oral Medication for RRMS

Hamburg : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Hamburg, HAMBURG : Research Center

Investigational Oral Medication for RRMS

Hanburg : Research Center

Investigational Oral Medication for RRMS

Hanburg : Research Center

Investigational Oral Medication for RRMS

Hannover, NIEDERSACHSEN : Research Center

Investigational Oral Medication for RRMS

Heidelberg, BADEN-WUTTEMBERG : Research Center

Investigational Oral Medication for RRMS

Jena, THURINGEN : Research Center

Investigational Oral Medication for RRMS

Köln, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

Leipzig, SACHSEN : Research Center

Investigational Oral Medication for RRMS

Lengerich : Research Center

Investigational Oral Medication for RRMS

Magdeburg, SACHSEN-ANHALT : Research Center

Investigational Oral Medication for RRMS

Marburg : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Marburg, HESSEN : Research Center

Investigational Oral Medication for RRMS

Minden, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

München, BAYERN : Research Center

Investigational Oral Medication for RRMS

München, BAYERN : Research Center

Investigational Oral Medication for RRMS

Münster, NORDRHEIN-WESTFALEN : Research Center

Investigational Oral Medication for RRMS

Osnabrück, NIEDERSACHSEN : Research Center

Investigational Oral Medication for RRMS

Regensburg, BAYERN : Research Center

Investigational Oral Medication for RRMS

Regensburg, BAYERN : Research Center

Investigational Oral Medication for RRMS

Schwerin, MECKLENBURG-VORPOMMERN : Research Center

Investigational Oral Medication for RRMS

Tübingen : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ulm : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Westerstede, NIEDERSACHSEN : Research Center

Investigational Oral Medication for RRMS

Greece

Athens, ATTICA : Research Center

Investigational Oral Medication for RRMS

Athens, ATTICA : Research Center

Investigational Oral Medication for RRMS

Guatemala : Research Center

Investigational Oral Medication for RRMS

Guatemala City : Research Center

Investigational Oral Medication for RRMS

Heraklion : Research Center

Investigational Oral Medication for RRMS

Ioannina : Research Center

Investigational Oral Medication for RRMS

Patras : Research Center

Investigational Oral Medication for RRMS

Thessaloniki : Research Center

Investigational Oral Medication for RRMS

Thessaloniki : Research Center

Investigational Oral Medication for RRMS

India

Bangalore : Research Center

Investigational Oral Medication for RRMS

Chandigarh : Research Center

Investigational Oral Medication for RRMS

Chennai : Research Center

Investigational Oral Medication for RRMS

Chennai : Research Center

Investigational Oral Medication for RRMS

Coimbatore : Research Center

Investigational Oral Medication for RRMS

Coimbatore : Research Center

Investigational Oral Medication for RRMS

Delhi : Research Center

Investigational Oral Medication for RRMS

Delhi : Research Center

Investigational Oral Medication for RRMS

Hyderabad : Research Center

Investigational Oral Medication for RRMS

Hyderabad : Research Center

Investigational Oral Medication for RRMS

Jaipur : Research Center

Investigational Oral Medication for RRMS

Kolkata : Research Center

Investigational Oral Medication for RRMS

Kolkata : Research Center

Investigational Oral Medication for RRMS

Lucknow : Research Center

Investigational Oral Medication for RRMS

Lucknow : Research Center

Investigational Oral Medication for RRMS

Mangalore : Research Center

Investigational Oral Medication for RRMS

Mangalore : Research Center

Investigational Oral Medication for RRMS

Mumbai : Research Center

Investigational Oral Medication for RRMS

Mumbai : Research Center

Investigational Oral Medication for RRMS

New Dehli : Research Center

Investigational Oral Medication for RRMS

New Delhi : Research Center

Investigational Oral Medication for RRMS

Pune : Research Center

Investigational Oral Medication for RRMS

Pune : Research Center

Investigational Oral Medication for RRMS

Ireland

Cork, Cork : Research Center

Investigational Oral Medication for RRMS

Dublin : Research Center

Investigational Oral Medication for RRMS

Israel

Ashkelon : Research Center

Investigational Oral Medication for RRMS

Beer Yaakov : Research Center

Investigational Oral Medication for RRMS

Holon : Research Center

Investigational Oral Medication for RRMS

Jerusalem : Research Center

Investigational Oral Medication for RRMS

Safed : Research Center

Investigational Oral Medication for RRMS

Tel Hashomer : Research Center

Investigational Oral Medication for RRMS

Italy

Milano : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Roma : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Roma : Research Center

Investigational Oral Medication for RRMS

Kazakhstan

Almata : Research Center

Investigational Oral Medication for RRMS

Almaty : Research Center

Investigational Oral Medication for RRMS

Almaty : Research Center

Investigational Oral Medication for RRMS

Astana : Research Center

Investigational Oral Medication for RRMS

Karaganda : Research Center

Investigational Oral Medication for RRMS

Karaganda : Research Center

Investigational Oral Medication for RRMS

Symkent : Research Center

Investigational Oral Medication for RRMS

Latvia

Riga : Research Center

Investigational Oral Medication for RRMS

Macedonia, The Former Yugoslav Republic of

Skopje : Research Center

Investigational Oral Medication for RRMS

Skopje : Research Center

Investigational Oral Medication for RRMS

Mexico

Aguascalientes : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Aguascalientes, Aguascalientes : Research Center

Investigational Oral Medication for RRMS

Chihuahua : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Chihuahua : Research Center

Investigational Oral Medication for RRMS

Chihuahua, Chih : Research Center

Investigational Oral Medication for RRMS

Guadalajara, Jal : Research Center

Investigational Oral Medication for RRMS

Guadalajara, JALISCO : Research Center

Investigational Oral Medication for RRMS

Merida, Yuc : Research Center

Investigational Oral Medication for RRMS

Mexico D.F : Research Center

Investigational Oral Medication for RRMS

Mexico, 14000 : Research Center

Investigational Oral Medication for RRMS

Mexico, DISTRITO FEDERAL : Research Center

Investigational Oral Medication for RRMS

Monterrey, NL : Research Center

Investigational Oral Medication for RRMS

Monterrey, NUEVO LEON : Research Center

Investigational Oral Medication for RRMS

Morelia, Michoacan : Research Center

Investigational Oral Medication for RRMS

Puebla, PUEBLA : Research Center

Investigational Oral Medication for RRMS

San Luis Potosi, SAN LUIS POTOSI : Research Center

Investigational Oral Medication for RRMS

Tijuana,Baja California : Research Center

Investigational Oral Medication for RRMS

Moldova

Chisinau : Research Center

Investigational Oral Medication for RRMS

Chisinau : Research Center

Investigational Oral Medication for RRMS

Netherlands

Breda : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Breda, NOORD-BRABANT : Research Center

Investigational Oral Medication for RRMS

Sittard, LIMBURG : Research Center

Investigational Oral Medication for RRMS

New Zealand

Christchurch : Research Center

Investigational Oral Medication for RRMS

Grafton, Auckland : Research Center

Investigational Oral Medication for RRMS

Hamilton : Research Center

Investigational Oral Medication for RRMS

Hamilton : Research Center

Investigational Oral Medication for RRMS

Poland

Bialystok, PODLASKIE : Research Center

Investigational Oral Medication for RRMS

Bialystok, PODLASKIE : Research Center

Investigational Oral Medication for RRMS

Bydgoszcz, KUJAWSKO-POMORSKIE : Research Center

Investigational Oral Medication for RRMS

Bydgoszcz, KUJAWSKO-POMORSKIE : Research Center

Investigational Oral Medication for RRMS

Gdansk : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Gdansk, POMORSKIE : Research Center

Investigational Oral Medication for RRMS

Gdansk, POMORSKIE : Research Center

Investigational Oral Medication for RRMS

Katowice, SLASKIE : Research Center

Investigational Oral Medication for RRMS

Katowice, SLASKIE : Research Center

Investigational Oral Medication for RRMS

Kraków, MALOPOLSKIE : Research Center

Investigational Oral Medication for RRMS

Kraków, MALOPOLSKIE : Research Center

Investigational Oral Medication for RRMS

Lodz : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lódz, LODZKIE : Research Center

Investigational Oral Medication for RRMS

Lódz, LODZKIE : Research Center

Investigational Oral Medication for RRMS

Lublin : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lublin, DOLNOSLASKIE : Research Center

Investigational Oral Medication for RRMS

Lublin, DOLNOSLASKIE : Research Center

Investigational Oral Medication for RRMS

Poznan, WIELKOPOLSKIE : Research Center

Investigational Oral Medication for RRMS

Poznan, WIELKOPOLSKIE : Research Center

Investigational Oral Medication for RRMS

Sosnowiec, SLASKIE : Research Center

Investigational Oral Medication for RRMS

Sosnowiec, SLASKIE : Research Center

Investigational Oral Medication for RRMS

Szczecin : Research Center

Investigational Oral Medication for RRMS

Szczecin : Research Center

Investigational Oral Medication for RRMS

Warszawa : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Warszawa, MAZOWIECKIE : Research Center

Investigational Oral Medication for RRMS

Warszawa, MAZOWIECKIE : Research Center

Investigational Oral Medication for RRMS

Wroclaw, DOLNOSLASKIE : Research Center

Investigational Oral Medication for RRMS

Wroclaw, DOLNOSLASKIE : Research Center

Investigational Oral Medication for RRMS

Zabrze, SLASKIE : Research Center

Investigational Oral Medication for RRMS

Zabrze, SLASKIE : Research Center

Investigational Oral Medication for RRMS

Puerto Rico

Guaynabo : Research Center

Investigational Oral Medication for RRMS

Romania

Bucresti : Research Center

Investigational Oral Medication for RRMS

Bucuresti : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bucuresti : Research Center

Investigational Oral Medication for RRMS

Bucuresti : Research Center

Investigational Oral Medication for RRMS

Cluj-Napoca, Cluj : Research Center

Investigational Oral Medication for RRMS

Iasi : Research Center

Investigational Oral Medication for RRMS

Oradea : Research Center

Investigational Oral Medication for RRMS

Targu Mures : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Timisoara, Timis : Research Center

Investigational Oral Medication for RRMS

Tirgu Mures : Research Center

Investigational Oral Medication for RRMS

Russian Federation

Ekaterinburg : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kazan : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Moscow : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nizhny Novgorod : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Tyumen : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Serbia

Belgrade : Research Center

Investigational Oral Medication for RRMS

Belgrade : Research Center

Investigational Oral Medication for RRMS

Kragujevac : Research Center

Investigational Oral Medication for RRMS

Kragujevac : Research Center

Investigational Oral Medication for RRMS

Nis : Research Center

Investigational Oral Medication for RRMS

Nis : Research Center

Investigational Oral Medication for RRMS

Novi Sad : Research Center

Investigational Oral Medication for RRMS

Novi Sad : Research Center

Investigational Oral Medication for RRMS

Slovakia

Banska Bystrica : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bratislava : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bratislava : Research Center

Investigational Oral Medication for RRMS

Bratislava : Research Center

Investigational Oral Medication for RRMS

Kosice : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kosice : Research Center

Investigational Oral Medication for RRMS

Kosice : Research Center

Investigational Oral Medication for RRMS

Martin, Zilina : Research Center

Investigational Oral Medication for RRMS

Martin, Zilina : Research Center

Investigational Oral Medication for RRMS

Nitra : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ruzomberok : Research Center

Investigational Oral Medication for RRMS

Spisska Nova Ves : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

South Africa

Cape Town, Western Cape : Research Center

Investigational Oral Medication for RRMS

Durban, KwaZulu-Natal : Research Center

Investigational Oral Medication for RRMS

Parow, Western Cape : Research Center

Investigational Oral Medication for RRMS

Rosebank : Research Center

Investigational Oral Medication for RRMS

Spain

Barcelona : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Barcelona, BARCELONA : Research Center

Investigational Oral Medication for RRMS

Córdoba, CORDOBA : Research Center

Investigational Oral Medication for RRMS

Madrid : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Madrid, MADRID : Research Center

Investigational Oral Medication for RRMS

Malaga : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Málaga, MALAGA : Research Center

Investigational Oral Medication for RRMS

Santiago de Compostela, LA CORUNA : Research Center

Investigational Oral Medication for RRMS

Sevilla : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sevilla, ANDALUCÍA : Research Center

Investigational Oral Medication for RRMS

Valencia : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Switzerland

Basel : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Basel, BASEL : Research Center

Investigational Oral Medication for RRMS

Sankt Gallen, SANKT GALLEN : Research Center

Investigational Oral Medication for RRMS

Zürich, ZURICH : Research Center

Investigational Oral Medication for RRMS

Turkey

Adana, ADANA : Research Center

Investigational Oral Medication for RRMS

Istanbul : Research Center

Investigational Oral Medication for RRMS

Izmir : Research Center

Investigational Oral Medication for RRMS

Trabzon : Research Center

Investigational Oral Medication for RRMS

Ukraine

Kharkiv, KHARKIV : Research Center

Investigational Oral Medication for RRMS

Kharkiv, KHARKIV : Research Center

Investigational Oral Medication for RRMS

Kharkov : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kiev : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kyiv, KIEV : Research Center

Investigational Oral Medication for RRMS

Kyiv, KIEV : Research Center

Investigational Oral Medication for RRMS

Kyiv, KIEV : Research Center

Investigational Oral Medication for RRMS

Lviv, LVIV : Research Center

Investigational Oral Medication for RRMS

Lviv, LVIV : Research Center

Investigational Oral Medication for RRMS

Odessa, ODESSA : Research Center

Investigational Oral Medication for RRMS

Odessa, ODESSA : Research Center

Investigational Oral Medication for RRMS

Poltava, POLTAVA : Research Center

Investigational Oral Medication for RRMS

Poltava, POLTAVA : Research Center

Investigational Oral Medication for RRMS

Propetrovsk : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Simferopol, CRIMEA : Research Center

Investigational Oral Medication for RRMS

Vinnitsa, VINNYTSYA : Research Center

Investigational Oral Medication for RRMS

Vinnytsya : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Zaporozhye, ZAPORIZHZHYA : Research Center

Investigational Oral Medication for RRMS

Zaporozhye, ZAPORIZHZHYA : Research Center

Investigational Oral Medication for RRMS

United Kingdom

Liverpool : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

London, ENGLAND : Research Center

Investigational Oral Medication for RRMS

Newcastle upon Tyne : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Newcastle upon Tyne, ENGLAND : Research Center

Investigational Oral Medication for RRMS

Nottingham : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Oxford, ENGLAND : Research Center

Investigational Oral Medication for RRMS

Sheffield : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sheffield, ENGLAND : Research Center

Investigational Oral Medication for RRMS

Staffordshire, ENGLAND : Research Center

Investigational Oral Medication for RRMS